Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 20054340
Calay D, et al. (2010) Inhibition of Akt signaling by exclusion from lipid rafts in normal and transformed epidermal keratinocytes. J Invest Dermatol 130, 1136-45 20054340
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T308-p - Akt1 (human)
Modsite: kDGAtMKtFCGtPEy SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): T308‑p, Akt1 iso2 (human): T246‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p
Characterization
Methods used to characterize site in vivo phosphoamino acid analysis, western blotting
Relevant cell lines - cell types - tissues:  HaCaT (keratinocyte)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
methyl-beta-cyclodextrin decrease
LY294002 decrease
wortmannin decrease
simvastatin no change compared to control
Filipin no change compared to control
cholesterol_oxidase increase
5-cholesten-5-beta-ol no change compared to control
cholesterol no change compared to control
methyl-beta-cyclodextrin cholesterol no change compared to control
AG1478 decrease
LY294002 decrease
methyl-beta-cyclodextrin decrease
AG1478 methyl-beta-cyclodextrin augment treatment-induced decrease
LY294002 methyl-beta-cyclodextrin augment treatment-induced decrease

S473-p - Akt1 (human)
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phosphoamino acid analysis, western blotting
Relevant cell lines - cell types - tissues:  HaCaT (keratinocyte)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
methyl-beta-cyclodextrin decrease
LY294002 decrease
wortmannin decrease
simvastatin decrease
Filipin no change compared to control
cholesterol_oxidase increase
5-cholesten-5-beta-ol decrease
AG1478 decrease
LY294002 decrease
methyl-beta-cyclodextrin decrease
AG1478 methyl-beta-cyclodextrin augment treatment-induced decrease
LY294002 methyl-beta-cyclodextrin augment treatment-induced decrease

T32-p - FOXO3A (human)
Modsite: QsRPRsCtWPLQRPE SwissProt Entrez-Gene
Orthologous residues
FOXO3A (human): T32‑p, FOXO3A (mouse): T32‑p, FOXO3A (rat): T32‑p
Characterization
Methods used to characterize site in vivo phosphoamino acid analysis, western blotting
Relevant cell lines - cell types - tissues:  HaCaT (keratinocyte)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
methyl-beta-cyclodextrin decrease
LY294002 decrease
wortmannin decrease

S2448-p - mTOR (human)
Modsite: RsRtRtDsysAGQsV SwissProt Entrez-Gene
Orthologous residues
mTOR (human): S2448‑p, mTOR (mouse): S2448‑p, mTOR (rat): S2448‑p
Characterization
Methods used to characterize site in vivo phosphoamino acid analysis, western blotting
Relevant cell lines - cell types - tissues:  HaCaT (keratinocyte)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
methyl-beta-cyclodextrin decrease
LY294002 decrease
wortmannin decrease

T412-p - p70S6K (human)
Modsite: NQVFLGFtyVAPsVL SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
Methods used to characterize site in vivo phosphoamino acid analysis, western blotting
Relevant cell lines - cell types - tissues:  HaCaT (keratinocyte)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
methyl-beta-cyclodextrin decrease
LY294002 decrease
wortmannin decrease
simvastatin decrease
Filipin no change compared to control
cholesterol_oxidase decrease
5-cholesten-5-beta-ol decrease
AG1478 decrease
LY294002 decrease

T444-p - p70S6K (human)
Modsite: RFIGsPRtPVsPVkF SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): T444‑p, p70S6K iso2 (human): T421‑p, p70S6K (mouse): T444‑p, p70S6K (rat): T444‑p, p70S6K iso2 (rat): T421‑p, p70S6K (fruit fly): S429‑p
Characterization
Methods used to characterize site in vivo phosphoamino acid analysis, western blotting
Relevant cell lines - cell types - tissues:  HaCaT (keratinocyte)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
methyl-beta-cyclodextrin no change compared to control
LY294002 no change compared to control
wortmannin no change compared to control
simvastatin no change compared to control
Filipin no change compared to control
cholesterol_oxidase no change compared to control
5-cholesten-5-beta-ol no change compared to control
AG1478 no change compared to control
LY294002 no change compared to control
methyl-beta-cyclodextrin no change compared to control
AG1478 methyl-beta-cyclodextrin no change compared to control
LY294002 methyl-beta-cyclodextrin no change compared to control

S447-p - p70S6K (human)
Modsite: GsPRtPVsPVkFsPG SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): S447‑p, p70S6K iso2 (human): S424‑p, p70S6K (mouse): S447‑p, p70S6K (rat): S447‑p, p70S6K iso2 (rat): S424‑p, p70S6K (fruit fly): S430‑p
Characterization
Methods used to characterize site in vivo phosphoamino acid analysis, western blotting
Relevant cell lines - cell types - tissues:  HaCaT (keratinocyte)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
methyl-beta-cyclodextrin no change compared to control
LY294002 no change compared to control
wortmannin no change compared to control
simvastatin no change compared to control
Filipin no change compared to control
cholesterol_oxidase no change compared to control
5-cholesten-5-beta-ol no change compared to control
AG1478 no change compared to control
LY294002 no change compared to control
methyl-beta-cyclodextrin no change compared to control
AG1478 methyl-beta-cyclodextrin no change compared to control
LY294002 methyl-beta-cyclodextrin no change compared to control

S241-p - PDK1 (human)
Modsite: skQARANsFVGtAQy SwissProt Entrez-Gene
Orthologous residues
PDK1 (human): S241‑p, PDK1 iso2 (human): S191‑p, PDK1 iso4 (human): S114‑p, PDK1 iso5 (human): S241‑p, PDK1 (mouse): S244‑p, PDK1 (rat): S244‑p
Characterization
Methods used to characterize site in vivo phosphoamino acid analysis, western blotting
Relevant cell lines - cell types - tissues:  HaCaT (keratinocyte)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
methyl-beta-cyclodextrin increase